ONYX Pharmaceuticals (ONXX)
News
| 1:15PM | Five Stocks to Watch as Cancer Drug Meeting Opens |
| 9:15AM | CHMP in Favor of Pfizer's Axitinib |
| 1:54 AM | Drug Stocks In The Spotlight At ASCO Conference. $JNJ $CELG $ONXX $RHHBY $PFE http://stks.co/42e8 by abubnic |
| May 30 | Drug Stocks In The Spotlight At Cancer Conference |
| May 30 | Conditions of Growth, Economic Analysis - Research Report on Qiagen NV and Onyx Pharm... |
| May 29 | Good article in NCI Cancer Bulletin explaining mechanism of Sorafenib http://stks.co/41UQ $ONXX by illinijill |
| May 29 | Onyx Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire |
| May 29 | Cell Therapeutics' JAK2 Inhibitor Acquisition Is A Smart Pick-Up |
| May 29 | $ONXX http://stks.co/40tU by Engi |
| May 29 | My Favorite Sector for Summer: Biotech Investor Place |
| May 28 | Top Trade Ideas for the Week of May 29, 2012: The Rest $ALL $CEO $HBI $JBHT $ONXX , Bonus Idea in the morning! by harmongreg |
| May 28 | 3 Reasons To Buy $ONXX http://stks.co/40JI by abubnic |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Onyx Pharmaceuticals Inc. is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. The company is focused on developing novel medicines that target key molecular pathways. The firm also develops and commercializes therapies designed to exploit the genetic and molecular differences between cancer cells and normal cells through partnerships. In 2009, the company acquired Proteolix, Inc., a private biotechnology company. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx was founded in 1992 by Frank McCormick Ph.D., FRS.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ONYX Pharmaceuticals is up 7.84% over the last year vs S&P 500 Total Return up 0.88%, AVEO Pharmaceuticals down 33.39%, and Exelixis down 60.28%.
- ONXX Total Returns
- ^SPXTR Total Returns
- AVEO Total Returns
- EXEL Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ONXX related companies
Pro Strategies Featuring ONXX
Did ONYX Pharmaceuticals make it into our Pro Portfolio Strategies?
ONXX Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ONXX Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ONXX | 45.78 | -0.07 | -0.15% | 2.938B |
| ONVI | 3.93 | +0.07 | +1.81% | 32.77M |
| ONTY | 3.62 | +0.00 | +0.00% | 157.87M |
| ONSM | 0.5797 | -0.00 | -0.05% | 7.009M |
| ONP | 1.93 | -0.13 | -6.31% | 38.03M |
| ONNN | 6.76 | +0.00 | +0.00% | 3.056B |
| ONFC | 10.06 | +0.13 | +1.31% | 69.51M |
| ONEQ | 111.73 | -0.43 | -0.38% | |
| ONE | 12.75 | -1.43 | -10.08% | 805.57M |
| ONCY | 3.40 | -0.07 | -2.02% | 265.18M |
